Dade Behring introduces in Europe assay for chronic alcohol abuse:
This article was originally published in Clinica
Dade Behring has launched in Europe what is claimed to be the first fully-automated and direct immunoassay test for the early detection of chronic alcohol abuse. The N Latex CDT assay is designed for use on the company's BNII and BN ProSpec systems. Studies indicate that patients suffering from chronic alcohol abuse are characterised by elevated levels of carbohydrate-deficient transferrin (CDT), a serum protein found in the blood. The marker can also be used to differentiate the diagnosis of alcohol and non-alcohol induced liver disease, the Deerfield, Illinois firm said. The assay is not yet available in the US. Research estimates that around 20% of patients seen in clinical practice present underlying alcohol misuse.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.